[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-355780-105":59,"doc-detail-355780-en":131},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":124,"head_meta":126,"extra_data":128,"updated_unix":130},105,"en","phase-iii-randomized-studies-of-mevrometostat-and-enzalutamide-in-metastatic-prostate-cancer-mevpro-1-and-mevpro-2-trial-protocols","Phase III randomized studies of mevrometostat and enzalutamide in metastatic prostate cancer (MEVPRO-1 and MEVPRO-2): trial protocols","","Phase I investigation of the enhancer of zeste homolog 2 inhibitor, mevrometostat, plus enzalutamide showed promising antitumor activity versus enzalutamide alone in metastatic castration-resistant prostate cancer (mCRPC). MEVPRO-1 (open label) and MEVPRO-2 (double blind) are ongoing global phase III randomized studies assessing efficacy and safety in mCRPC. MEVPRO-1 targets ~600 patients previously treated with abiraterone; MEVPRO-2 targets ~900 androgen receptor pathway inhibitor-naïve patients. Patients receive mevrometostat plus enzalutamide, or control regimens; the primary endpoint is rPFS with overall survival as a secondary objective.",{"@graph":69,"@context":123},[70,84,106],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/phase-iii-randomized-studies-of-mevrometostat-and-enzalutamide-in-metastatic-prostate-cancer-mevpro-1-and-mevpro-2-trial-protocols/355780/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/phase-iii-randomized-studies-of-mevrometostat-and-enzalutamide-in-metastatic-prostate-cancer-mevpro-1-and-mevpro-2-trial-protocols/355780.png","ImageObject",300,407,{"name":92,"@type":93},"Pentious","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-03","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":105},"InteractionCounter",{"@type":104},"ViewAction",17,{"@type":107,"mainEntity":108},"FAQPage",[109,115,119],{"name":110,"@type":111,"acceptedAnswer":112},"What are MEVPRO-1 and MEVPRO-2 studying?","Question",{"text":113,"@type":114},"MEVPRO-1 and MEVPRO-2 study whether adding mevrometostat to enzalutamide benefits patients with metastatic castration-resistant prostate cancer by slowing cancer progression. Both are ongoing international phase III randomized trials.","Answer",{"name":116,"@type":111,"acceptedAnswer":117},"Who is eligible for MEVPRO-1 versus MEVPRO-2?",{"text":118,"@type":114},"MEVPRO-1 includes about 600 patients with prior abiraterone treatment history, while MEVPRO-2 includes about 900 patients who have not previously received abiraterone or other androgen-receptor pathway inhibitor therapies. Both require specified ECOG performance status and testosterone thresholds.",{"name":120,"@type":111,"acceptedAnswer":121},"What is the primary endpoint and how are patients treated?",{"text":122,"@type":114},"The primary endpoint is radiographic progression-free survival (rPFS) assessed by blinded independent central review. Treatment is randomized 1:1 to mevrometostat plus enzalutamide versus control (enzalutamide choices with docetaxel in MEVPRO-1, and enzalutamide alone in MEVPRO-2).","https://schema.org",{"og:url":83,"og:type":125,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":127,"canonical":83},"index,follow",{"doc_id":129,"site_id":62},355780,1790196627,{"code":4,"msg":5,"data":132},{"doc_id":129,"user_id":133,"nickname":92,"user_avatar":134,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":105,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":140,"language":141,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":142,"faqs":143,"seo_title":144,"seo_description":67,"update_tm":145,"read_time":41,"preview_page_count":19,"preview_urls":146},1374404730887,"https://ap-avatar.wpscdn.com/davatar_6f874abed73319feea01a86fa6f0fab8","FUTURE ONCOLOGY  \n2026, VOL. 22, NO. 12, 1397–1408  \n[https://doi.org/10.1080/14796694.2026.2667441](https://doi.org/10.1080/14796694.2026.2667441)  \nCLINICAL TRIAL PROTOCOL  \nPhase III randomized studies of mevrometostat and enzalutamide in metastatic prostate cancer (MEVPRO-1 and MEVPRO-2): trial protocols  \nNeal D. Shore a, Karim Fizazib, Michael Thomas Schweizerc,d, Elena Castroe, Arun A. Azadf, Daniel J. Georgeg, Karine Martins da Trindadeh,i, Hao Zengj, Nitin Shrivastavak, Svitlana Tonkovydl, Amy Bockm, Srilakshmi Nekkalapudin, Yiyun Tango, Stella Linn and Neeraj Agarwalp  \naSTART Carolinas/Carolina Urologic Research Center, Myrtle Beach, SC, USA; bDepartment of Cancer Medicine, Centre Oscar Lambret, Institut Gustave Roussy, University of Paris Saclay, Lille, France; cDivision of Medical Oncology, University of Washington, Seattle, WA, USA; dClinical Research Division, Fred Hutchinson Cancer Center, Seattle, WA, USA; e Department of Medical Oncology, Hospital Universitario 12 de Octubre, Madrid, Spain; fDepartment of Medical Oncology, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia; gDuke Cancer Institute, Duke University School of Medicine, Durham, NC, USA; hLatin American Cooperative Oncology Group, Genitourinary Group (LACOG-GU), Porto Alegre, Brazil; iDivision of Oncology, Instituto D’Or de Pesquisa e Ensino, Fortaleza, Brazil; jDepartment of Urology, Institute of Urology, West China Hospital, Sichuan University, Chengdu, Sichuan, China; kOncology, Pfizer Inc., South San Francisco, CA, USA; lOncology, Pfizer Poland, Warsaw, Poland; mOncology, Pfizer Inc., Cambridge, MA, USA; nOncology, Pfizer Inc., New York, NY, USA; o Biostatistics Oncology, Global Biometrics and Data Management, Pfizer Inc., South San Francisco, CA, USA; pHuntsman Cancer Institute (NCI-CCC), University of Utah, Salt Lake City, UT, USA  \nABSTRACT  \nPhase I investigation of the enhancer of zeste homolog 2 inhibitor, mevrometostat, plus enzalutamide showed promising antitumor activity versus enzalutamide alone in patients with metastatic castration-resistant prostate cancer (mCRPC) (NCT03460977). MEVPRO-1 (open label) and MEVPRO-2 (double blind) are ongoing, global, phase III, randomized studies evaluating efficacy and safety of mevrometostat plus enzalutamide inpatients with mCRPC. MEVPRO-1 will include ~600 patients with ≥12 weeks of prior abiraterone treatment, Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0–2, testosterone ≤50 ng/dL, and life expectancy ≥6 months. MEVPRO-2 will include ~900 androgen receptor pathway inhibitor-naïve patients, with ECOG PS 0–1, testosterone ≤50 ng/dL, and life expectancy ≥12 months. Patients are randomized 1:1 tomevrometostat (875 mg twice daily with food) plus enzalutamide (160 mg once daily), or physician’s choice of enzalutamide or docetaxel (MEVPRO-1) or enzalutamide (MEVPRO-2). Primary endpoint is radiographic progression-free survival (rPFS) per Response Evaluation Criteria in Solid Tumors 1.1 (soft tissue) and Prostate Cancer Working Group 3 criteria (bone) assessed by blinded independent central review. Overall survival is a secondary objective. Kaplan–Meier analysis will summarize time-to-event endpoints. Safety will be assessed. Results will evaluate whether mevrometostat plus enzalutamide can provide clinical benefit in patients with mCRPC.  \nClinical trial registration: [www.clinicaltrials.gov](www.clinicaltrials.gov) identifiers are NCT06551324 (MEVPRO-1) and NCT06629779 (MEVPRO-2) .  \nPLAIN LANGUAGE SUMMARY  \nWhat is this summary about?  \nThis summary describes two ongoing, large, international clinical trials: MEVPRO-1 and MEVPRO-2. The trials will study a new treatment approach for patients with metastatic castration-resistant prostate cancer, a type of prostate cancer that has spread and no longer responds to standard hormone treatments.  \nWhich medicines are being tested?  \nThe trials are testing mevrometostat, a new medicine that blocks a protein called enhancer o","cbCaissgu110f9RE","https://ap.wps.com/l/cbCaissgu110f9RE","pdf",6263726,12,"English","# Abstract\n## Plain language summary\n## Article history\n## Keywords","[{\"question\":\"What are MEVPRO-1 and MEVPRO-2 studying?\",\"answer\":\"MEVPRO-1 and MEVPRO-2 study whether adding mevrometostat to enzalutamide benefits patients with metastatic castration-resistant prostate cancer by slowing cancer progression. Both are ongoing international phase III randomized trials.\"},{\"question\":\"Who is eligible for MEVPRO-1 versus MEVPRO-2?\",\"answer\":\"MEVPRO-1 includes about 600 patients with prior abiraterone treatment history, while MEVPRO-2 includes about 900 patients who have not previously received abiraterone or other androgen-receptor pathway inhibitor therapies. Both require specified ECOG performance status and testosterone thresholds.\"},{\"question\":\"What is the primary endpoint and how are patients treated?\",\"answer\":\"The primary endpoint is radiographic progression-free survival (rPFS) assessed by blinded independent central review. Treatment is randomized 1:1 to mevrometostat plus enzalutamide versus control (enzalutamide choices with docetaxel in MEVPRO-1, and enzalutamide alone in MEVPRO-2).\"}]","Phase III randomized studies of mevrometostat and enzalutamide in metastatic prostate cancer (MEVPRO-1 and MEVPRO-2): trial protocols | PDF",1790120931,[147,151,155,159],{"page_no":8,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/236e604b605f6939c51d02ed52c75b11.webp",983,1280,{"page_no":14,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/0bdd6e9a1cbd25b0a1a61a81a67dd82d.webp",982,1278,{"page_no":81,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/6b42e4cbb1485681a54dd77789386e71.webp",981,1277,{"page_no":19,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/c93dff70f02d11a6e9a9001b2709aefe.webp",980,1276]